市场见解

The Starpharma (ASX: SPL) share price surges on Vietnam launch

The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will…
The post The Starpharma (ASX: SPL) share price surges on Vietnam launch appeared first on The Motley Fool Australia. –

The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will be launched in Vietnam this week.

The biotech registered its VIRALEZE spray for sale in the Asian country. It recently signed initial distribution agreements to supply 100,000 units and said it is finalising a contract for ongoing supply of the product.

The Starpharma share price jumped 6.5% to $1.16 at the time of writing when the  S&P/ASX 200 Index (Index:^AXJO) dipped 0.3%.

Vietnam boost for the Starpharma share price

The spray is a broad-spectrum antiviral nasal spray that contains Starpharma’s SPL7013 innovation. Tests have shown that SPL7013 caused the inactivation of more than 99.9% of the Delta COVID-19 mutation.

The initial distribution agreements were signed with Healthco Australia  Pty  Ltd and Vietnam-based Truong Bao Land International Investment  Company  Limited  (TBL).  TBL will also distribute VIRALEZE via its local medical distribution networks.

Starpharma share price breathing easier

This development couldn’t have come at a better time for embattled shareholders. The Starpharma share price has slumped by more than 20% this calendar year. Even with today’s rally, it is still trading close to an 18-month low.

However, the emergence of the Omicron mutation could put COVID-linked ASX shares back into investors’ good books.

From Delta to Omicron

Starpharma trying to capitalise on this by hinting that VIRALEZE could lower the risk of mutations too.

It noted that the mechanism of action meant that mutations of the spike protein that make SARS-CoV-2 more infectious appear to make the virus more susceptible to trapping and blocking by SPL7013.

“We are excited to see the product launched in Vietnam this week,” said Jackie  Fairley,  Starpharma’s chief executive.

“This registration, the first in South East Asia, builds upon existing submissions as well as registrations already achieved in Europe, India and New Zealand, and we are expediting further regulatory submissions in multiple regions and countries.”

Other ASX shares of note

The Starpharma share price isn’t the only one in the sector that is making gains. The IDT Australia Limited (ASX: IDT) share price gained 0.8% to 61.5 cents and the CSL Limited (ASX: CSL) share price added 0.9% to $309.53.

IDT is the first in Australia to develop a manufacturing capability for mRNA vaccines.

The IDT share price jumped by nearly three-fold in 2021 while the CSL share price gained a little over 8%.

The post The Starpharma (ASX: SPL) share price surges on Vietnam launch appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

More reading

ASX 200 (ASX:XJO) midday update: ANZ hit with class action, GUD sinks

These were the 5 worst performing ASX 200 shares in November

These were the 5 best performing ASX 200 shares in November

2 ASX dividend shares that could provide rock-solid income

Advisor reveals the 3 most popular ASX shares among his clients

Motley Fool contributor Brendon Lau owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!